Skip to main
TELA

TELA Stock Forecast & Price Target

TELA Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

TELA Bio Inc. has demonstrated significant growth potential, evidenced by a 22% increase in OviTex unit sales and a 3% rise in OviTex PRS unit sales for the quarter, alongside a sequential revenue improvement of 2% despite facing leadership transitions. The company's recent financial maneuvers, including a $13 million equity raise and an upsizing of debt capacity, have enhanced its cash runway, positioning it well for continued investment in sales force expansion and product development as it targets over 90 territory managers by early 2026. Furthermore, TELA's structured approach to improving productivity and establishing an achievable sales growth floor for 2026 indicates a commitment to sustainable growth amid a recalibrated outlook, reinforcing a positive trajectory for the company's financial performance.

Bears say

TELA Bio Inc. has reduced its revenue guidance for 2025, projecting at least 16% growth year-over-year, which translates to a minimum of $80.4 million, down from previous expectations of $85.0 million to $88.0 million reflecting a growth rate of 23-27%. The company also indicated early projections for 2026 growth at a minimum of 15%, further signaling a slowdown in anticipated revenue growth. Additionally, while operating expenses were lower than expected, the gross margin of 67.5% fell short of targets by 200 basis points and represented a decline compared to previous periods, contributing to a missed operating income target and reflecting broader operational challenges.

TELA has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TELA Bio, Inc. (TELA) Forecast

Analysts have given TELA a Buy based on their latest research and market trends.

According to 5 analysts, TELA has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TELA Bio, Inc. (TELA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.